Relugolix
- Generic Name
- Relugolix
- Brand Names
- Myfembree, Orgovyx
- Drug Type
- Small Molecule
- Chemical Formula
- C29H27F2N7O5S
- CAS Number
- 737789-87-6
- Unique Ingredient Identifier
- P76B05O5V6
- Background
Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids, and more recently by the United States' FDA in 2020, under the brand name Orgovyx, for the treatment ...
- Indication
适用于治疗成年晚期前列腺癌症患者。
- Associated Conditions
- Advanced Hormone Sensitive Prostate Cancer, Advanced Prostate Cancer, Heavy Menstrual Bleeding, Severe Pain
- Associated Therapies
- -
Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
- Conditions
- Interventions
- First Posted Date
- 2024-11-04
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT06671548
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, China
REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial
- Conditions
- Interventions
- First Posted Date
- 2024-10-21
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Emory University
- Target Recruit Count
- 72
- Registration Number
- NCT06650579
- Locations
- 🇺🇸
Emory Proton Therapy Center, Atlanta, Georgia, United States
🇺🇸Winship at Emory Midtown, Atlanta, Georgia, United States
🇺🇸Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-10-08
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- AdventHealth
- Target Recruit Count
- 30
- Registration Number
- NCT06631521
- Locations
- 🇺🇸
AdventHealth Orlando, Orlando, Florida, United States
Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial
- Conditions
- Interventions
- First Posted Date
- 2024-07-15
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 50
- Registration Number
- NCT06499870
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
Description of Relugolix Use in Patients With Prostate Cancer Within the VHA
- First Posted Date
- 2024-06-17
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 500
- Registration Number
- NCT06462014
- Locations
- 🇺🇸
Pfizer, New York, New York, United States
Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED)
- Conditions
- Interventions
- First Posted Date
- 2024-06-17
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Atish Choudhury, MD
- Target Recruit Count
- 33
- Registration Number
- NCT06463457
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Stereotactic Body Radiation Therapy Plus Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy for Treatment of Metastatic, Recurrent Hormone-Sensitive Prostate Cancer, DIVINE Trial
- Conditions
- Interventions
- Drug: AbirateroneDrug: ApalutamideProcedure: Biospecimen CollectionProcedure: Bone ScanProcedure: Computed TomographyDrug: DarolutamideDrug: DegarelixDrug: EnzalutamideDrug: GoserelinDrug: HistrelinDrug: LeuprolideProcedure: Magnetic Resonance ImagingOther: Patient ObservationProcedure: Positron Emission TomographyDrug: PrednisoneOther: Questionnaire AdministrationDrug: RelugolixRadiation: Stereotactic Body Radiation TherapyDrug: Triptorelin
- First Posted Date
- 2024-04-23
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 120
- Registration Number
- NCT06378866
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer
- First Posted Date
- 2024-03-26
- Last Posted Date
- 2024-03-26
- Target Recruit Count
- 70
- Registration Number
- NCT06330805
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- University of Kansas Medical Center
- Target Recruit Count
- 90
- Registration Number
- NCT06129851
- Locations
- 🇺🇸
University of Kansas Cancer Center, Kansas City, Kansas, United States
RecoverPC: Relugolix vs GnRH Agonist in Quality of Life
- Conditions
- Interventions
- First Posted Date
- 2023-03-13
- Last Posted Date
- 2024-02-14
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 110
- Registration Number
- NCT05765500
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute at Foxborough, Foxboro, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.